CSL's $450M bet on uniQure's hemophilia gene therapy tops Wednesday's deals roundup, along with a two-program neuro partnership between Merck and Yumanity $CSL $QURE $MRK $EDIT $LJPC $TTPH https://t.co/uHJnB0swLl